Home / Market Reports / Pharma & Healthcare / Global Andrographis Paniculana Injection Market Growth 2024-2030

Global Andrographis Paniculana Injection Market Growth 2024-2030

Global Andrographis Paniculana Injection Market Growth 2024-2030

Product Code:1241718

Published Date: Nov 29,2024

Pages: 129

Region: Global

Category: Pharma & Healthcare

PDF DOWNLOAD

GET FREE SAMPLE

CUSTOMIZE REQUEST

PDF DOWNLOAD

GET FREE SAMPLE

CUSTOMIZE REQUEST

SELECT A FORMAT

ADD TO BASKET

BUY NOW

Provide comprehensive and accurate analysis and reports according to your exact requirements

Provide comprehensive and accurate analysis and reports according to your exact requirements

CONTACT US 

The global Andrographis Paniculana Injection market size is predicted to grow from US$ 33 million in 2024 to US$ 42.3 million in 2030; it is expected to grow at a CAGR of 4.2% from 2024 to 2030.

Andrographis paniculata injection is a traditional Chinese medicine preparation, the main ingredient of which is the active ingredient extracted from Andrographis paniculata. Andrographis paniculata is a perennial herb widely distributed in tropical and subtropical regions of Asia, and has pharmacological effects such as clearing away heat and detoxification, anti-inflammatory and antibacterial.

United States market for Andrographis Paniculana Injection is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

China market for Andrographis Paniculana Injection is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

Europe market for Andrographis Paniculana Injection is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

Global key Andrographis Paniculana Injection players cover Langzhi Group Wanrong Pharmaceutical Co., Ltd., Shanxi Huawei Pharmaceutical Co., Ltd., Zhengda Qingchunbao Pharmaceutical Co., Ltd., Changchun Dazheng Pharmaceutical Technology Co., Ltd., Henan Kanghua Pharmaceutical Co., Ltd., etc. In terms of revenue, the global two largest companies occupied for a share nearly 
 % in 2023.

LP Information, Inc. (LPI) ' newest research report, the “Andrographis Paniculana Injection Industry Forecast” looks at past sales and reviews total world Andrographis Paniculana Injection sales in 2023, providing a comprehensive analysis by region and market sector of projected Andrographis Paniculana Injection sales for 2024 through 2030. With Andrographis Paniculana Injection sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Andrographis Paniculana Injection industry.

This Insight Report provides a comprehensive analysis of the global Andrographis Paniculana Injection landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Andrographis Paniculana Injection portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Andrographis Paniculana Injection market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Andrographis Paniculana Injection and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Andrographis Paniculana Injection.

This report presents a comprehensive overview, market shares, and growth opportunities of Andrographis Paniculana Injection market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:
    2ml
    5ml
    10ml
    Others

Segmentation by Application:
    Hospital
    Clinic
    Other

This report also splits the market by region:
    Americas
        United States
        Canada
        Mexico
        Brazil
    APAC
        China
        Japan
        Korea
        Southeast Asia
        India
        Australia
    Europe
        Germany
        France
        UK
        Italy
        Russia
    Middle East & Africa
        Egypt
        South Africa
        Israel
        Turkey
        GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
    Langzhi Group Wanrong Pharmaceutical Co., Ltd.
    Shanxi Huawei Pharmaceutical Co., Ltd.
    Zhengda Qingchunbao Pharmaceutical Co., Ltd.
    Changchun Dazheng Pharmaceutical Technology Co., Ltd.
    Henan Kanghua Pharmaceutical Co., Ltd.
    Hainan Pharmaceutical Factory Co., Ltd.
    Guangdong Leiyunshang Pharmaceutical Co., Ltd.
    Wuxi Jiyushanhe Pharmaceutical Co., Ltd.
    Jiangxi Kangenbei Tianshikang Pharmaceutical Co., Ltd.
    Lizhu Group Limin Pharmaceutical Factory
    Jiangsu Kangyuan Pharmaceutical Co., Ltd.
    Jiangxi Yuankang Judu Pharmaceutical Co., Ltd.
    Shenwei Pharmaceutical (Sichuan) Co., Ltd.
    Shanxi Kangyi Pharmaceutical Co., Ltd.
    Jiangsu Hengfeng Pharmaceutical Co., Ltd.
    Guangdong Luofushan National Pharmaceutical Co., Ltd.
    Guangdong Xinfeng Pharmaceutical Co., Ltd.

Key Questions Addressed in this Report
What is the 10-year outlook for the global Andrographis Paniculana Injection market?
What factors are driving Andrographis Paniculana Injection market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Andrographis Paniculana Injection market opportunities vary by end market size?
How does Andrographis Paniculana Injection break out by Type, by Application?